Skip to main content
Sophie Binder, Gregor Hagelüken, Niels Schneberger in the laboratory

News categories: Publication

Gene scissors switch off with built-in timer

Bonn researchers clarify self-regulation of the immune response in the CRISPR bacterial defense system

CRISPR gene scissors, as new tools of molecular biology, have their origin in an ancient bacterial immune system. But once a virus attack has been successfully overcome, the cell has to recover. Researchers from the University Hospital Bonn (UKB) and the University of Bonn, in cooperation with researchers from the Institut Pasteur in France, have discovered a timer integrated into the gene scissors that enables the gene scissors to switch themselves off. The results of the study have been published in the renowned journal "Nucleic Acids Research".

Some bacteria have developed CRISPR gene scissors in response to attacks by so-called phages. This bacterial immune system recognizes the phage genetic material, destroys it and thus protects against viral attacks. When detecting phages, the type III variants of these immune systems produce messenger substances with cyclic oligoadenylates (cOAs), which the bacteria use to switch on a complex emergency plan. This ensures that a virus can be fought optimally and on a broad front. A research team led by PD Dr. Gregor Hagelueken from the Institute of Structural Biology at the UKB, who is a member of the Transdisciplinary Research Area (TRA) "Life & Health" and the Cluster of Excellence ImmunoSensation2 at the University of Bonn, discovered that the messenger substance cA4 produced by the gene scissors binds to a protein called CalpL. The protein scissors activated in this way trigger a signaling cascade that helps the cell to survive the viral attack.

The Bonn researchers had thus uncovered a completely new aspect of CRISPR systems, which can be easily reprogrammed for biotechnological and medical purposes. "These CRISPR-activated protein scissors that we discovered are a brand new tool in the toolbox of molecular biology," says Niels Schneberger, a doctoral student at the University of Bonn's Institute of Structural Biology at the UKB, who played a key role in the discovery of the CalpL protein.

 

Cellular recovery by limiting the antiviral response

"After a viral attack, however, it is crucial to eliminate the remaining cyclic oligoadenylates in order to terminate the antiviral reaction and return the cell to its normal state," says Sophie Binder, who shares the first authorship of the study with Schneberger and is also a doctoral student at the University of Bonn's Institute of Structural Biology at the UKB. In cooperation with researchers from the Institut Pasteur in Paris and the Kekulé Institute for Organic Chemistry and Biochemistry at the University of Bonn, the Bonn researchers have now been able to show that the so-called SAVED domain of the CalpL protease has a ring nuclease activity that cleaves cA4. "The protein therefore contains something like a molecular timer that switches off the immune reaction. By breaking down cA4 into linear fragments, the duration of the immune response is regulated, which enables a controlled return of the cell to normal conditions," says Binder.

A switchable protease such as CalpL is also of great interest for biotechnological applications. For example, it could be used as a molecular sensor. "The newly discovered ring nuclease activity is actually a disadvantage for such purposes," says PD Dr. Hagelueken. "However, in our study, we were also able to show how ring nuclease activity can be specifically inhibited so that the sensor does not switch itself off again.”

 

Sponsorship

The project was funded by the German Research Foundation (DFG) and the Open Access Publication Fund of the University of Bonn. In addition to the Institute of Structural Biology at the UKB, the Kekulé Institute of Organic Chemistry and Biochemistry at the University of Bonn and the Institut Pasteur, Paris, France, are also involved in the study.

 

Publication

Sophie C. Binder, Niels Schneberger, Marianne Engeser, Matthias Geyer, Christophe Rouillon, Gregor Hagelueken: The SAVED domain of the type III CRISPR protease CalpL is a ring nuclease; Nucleic Acids Research, 
DOI: https://doi.org/10.1093/nar/gkae676

Related news

Mikrochip zur Wiederherstellung zentralen Sehvermögens bei fortgeschrittener Makuladegeneration.

News categories: Publication

Approval of a Novel Retinal Implant Technology

A novel retinal implant is offering people with geographic atrophy the opportunity to regain part of their central vision for the first time. Geographic atrophy is a severe late stage of age-related macular degeneration. An international research team led by Prof. Frank G. Holz of the UKB and the University of Bonn demonstrated in an international clinical trial that the majority of participants experienced significant improvements in visual acuity. The novel retinal implant technology has now received approval for routine clinical use in Europe, making it available beyond clinical trials.
View entry
Authors

News categories: Publication

The Gut as a Key Player in Immunotherapy for MS

B-cell depletion therapies, in which B cells of the immune system, which may drive disease activity in multiple sclerosis (MS), are temporarily removed, have contributed significantly to improved treatment for patients in recent years. Researchers from Bonn, along with their collaborators, have uncovered a previously unknown mechanism through which B-cell depletion therapies contribute to a better disease course in patients with MS. Surprisingly, the treatment appears to exert part of its beneficial effect by mobilizing regulatory immune cells that naturally reside in the gut.
View entry
Dr. Ivana Jorgacevic und Prof. Dr. Rayk Behrendt have discovered that the inflammatory messenger substance interferon-alpha can trigger Sjögren's syndrome: The researchers in Bonn.

News categories: Publication

New test points to precision treatment for autoimmune condition

Interferon alpha is an inflammatory mediator that can cause Sjögren’s syndrome, an autoimmune disease. This is revealed in a recent study carried out by the University Hospital Bonn together with the University of Bonn, the University of Edinburgh and Newcastle University. Their findings, which have been published in the journal “Lancet Rheumatology,” could make it easier in the medium term to develop drugs to fight this chronic condition.
View entry

Back to the news overview